Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label randomized phase 3 study of daridorexant in adults with insomnia disorder
jRCT2080225348Phase 3Completed
- Sponsor
- Idorsia
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daridorexant in Insomnia (2 arms), sponsored by Idorsia. Primary endpoint: Long-term safety and tolerability. Started Aug 2020; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2080225348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225348.